References
- Bratt O, Carlsson S, Fransson P, et al. The Swedish National Guidelines on Prostate Cancer Part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;2022:1–9.
- Bratt O, Carlsson S, Fransson P, et al. The Swedish National Guidelines on Prostate Cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;2022:1–7.
- www.npcr.se/RATTEN. Accessed 19 July 2022.
- Franck Lissbrant I, Hjälm Eriksson M, Lambe M, et al. Set-up and preliminary results from the patient-overview prostate cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227–234.
- Widmark A, Klepp O, Solberg A, et al. Scandinavian prostate cancer group study 7; Swedish association for urological oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308.
- Liedberg F, Kjellström S, Lind A-K, et al. Swedish national guidelines on urothelial carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56(2):137–146.
- https://cancercentrum.se/samverkan/cancerdiagnoser/urinblasa-urinvagar/kvalitetsregister/rapporter/. Accessed 19 July 2022.